secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bioventus Inc. (BVS)
CIK:        0001665988
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001665988-26-000026
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioventus Q1 revenue up 7% to $132.1M; GAAP EPS $0.04, raises FY26 EPS and CFO guidance
--------------------------------------------------------------------------------

- Revenue $132.1M (+7% YoY); GAAP EPS $0.04 vs -$0.04; Non-GAAP EPS $0.15 vs $0.08 (+88%).
- Adjusted EBITDA $23.9M (+24% from $19.2M); cash from ops $8.9M vs -$19.3M.
- Pain Treatments +7.7%, Surgical Solutions +6.2%, Restorative Therapies +4.6%; International +17.1%.
- Raised FY26 Adj EPS guidance to $0.75-$0.79 (up $0.02), CFO to $84-$89M (up $2M); reaffirms rev $600-610M.
- Discretionary $22M term loan prepayment on Mar 27 reduces debt and future interest.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1665988/000166598826000026/0001665988-26-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1665988/000166598826000026/bvs-20260506.htm
  HTML page:      https://secwatch.observer/filing/0001665988-26-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer